ArticleParasites & vectors2026
A multicentric study on understanding the bionomics of Indian malaria vectors across diverse eco-epidemiological settings.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndia aims to eliminate malaria by 2030; however, a thorough understanding of the current biology and behavior of vector species will facilitate the efforts. Vector species often alter their biting and resting behaviors in response to long-term chemical control measures, posing significant challenges to ongoing vector control interventions. Therefore, it is essential to investigate and update our knowledge of the bionomics of malaria vectors in the current context.
methodsThis study was carried out across 14 districts in eight Indian states between 2021 and 2023, employing various entomological techniques. Anopheles mosquito species were tested for human blood meal preference and Plasmodium infection using polymerase chain reaction (PCR). Insecticide susceptibility status was assessed according to World Health Organization (WHO) protocols, and key metrics, such as degree of exophily, trap density, human biting rate (HBR), and man-hour density (MHD), were determined to understand mosquito abundance and behavior.
resultsAnopheles culicifacies, a major malaria vector species, was found in all study states. The highest indoor MHD of this species was 11.95, recorded in the Kanker district of Chhattisgarh, whereas 27.16 was the highest outdoor MHD as observed in the Bareilly district of Uttar Pradesh. In Assam and Tripura, Anopheles minimus exhibited differential resting behavior, whereas An. baimaii was found to be exophilic in Kokrajhar, Udalguri, and South Tripura. An. stephensi showed endophilic behavior with an indoor MHD of 4.36 in Barmer. An. minimus exhibited high anthropophagic behavior, with a human blood index of 0.94 in South Tripura. A high sporozoite infection rate was observed in An. baimaii (5.88) compared with the other vector species. An. culicifacies was found to be resistant to alpha-cypermethrin (0.05%) in the Jagdalpur and Kanker districts, with possible resistance in Barmer study sites, and resistant to deltamethrin (0.05%) in Kanker, Surendranagar, and Dahod. An. stephensi showed resistance to multiple insecticides in the North Goa.
conclusionsAn. culicifacies was prevalent in all eight study states, with a higher abundance in Kanker and Bareilly. Changes in the resting behavior of An. minimus in Tripura, and insecticide resistance that has developed in An. culicifacies and An. stephensi against pyrethroids poses a significant concern. The findings of this study will aid in implementing effective vector control strategies in India's pre-elimination efforts against malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.